Abstract:OBJECTIVE: Several epidemiological studies have indicated that the long‐term administration of non‐steroidal anti‐inflammatory drugs (NSAIDs) may reduce the incidence of colorectal cancer. The best known action of NSAIDs is to block cyclooxygenase, the key enzyme required for the conversion of arachidonic acid to prostaglandins. Two cyclooxygenase isoforms have been identified and these are referred to as COX‐1 and COX‐2. Recent studies indicate that inducible COX‐2 plays an important role in gastrointestinal inflammation and carcinogenesis. The present study was undertaken to investigate the expression and clinical implications of COX‐2 and COX‐1 in normal and diseased colons. METHODS: COX‐2 and COX‐1 protein expression in specimens from normal controls and diseased colon tissues were examined semiquantitatively by using immunohistochemical methods. RESULTS: By using immunohistochemical detection methods, low COX‐2 protein expression in colonic epithelial cells was observed in 20.0% (2/10) of normal controls. Eighty percent (16/20) of specimens from inflammatory bowel disease (IBD) had a high COX‐2 expression, 46.40% (13/28) of adenomas and 64.3% of (9/14) well‐differentiated colonic carcinomas had some COX‐2 protein expression. Expression of COX‐2 protein was increased in IBD and colonic carcinomas compared with normal controls. There were no significant differences between colonic adenomas and colonic carcinomas. No correlation was found between COX‐2 protein expression and patient gender, patient age, tumor size, tumor location or the degree of differentiation/ metastasis of the tumor. Strong immunoreactive COX‐2 was expressed in clusters in interstitial cells (mainly mononuclear cells) in 53.6% (15/28) of adenomas and 64.3% (9/14) of colonic carcinomas. Strong COX‐2 protein expression was also displayed in the normal glands that were adjacent to the adenomas and carcinomas. Expression of COX‐1 protein was observed in the epithelial cells and interstitial cells or tumor cells of normal colon, IBD, colonic adenomas and colonic carcinomas. CONCLUSIONS: Our results indicated that COX‐2 protein overexpression may contribute to the development of IBD and colonic carcinogenesis.

[Expression of Cyclooxygenase 2 Mrna in Apical Periodontitis].

Expression of cyclooxygenase 2 in colorectal cancer

Immunohistochemical evaluation of cyclooxygenase-2 and mast cell density in periapical lesions

Expression of COX-2 in uterine adenomyosis and its clinical significance

Relationship Between Expression of COX-2 and Clinicopathological Characteristics in Human Gastric Cancer

Expression of cyclooxygenase-2 (COX-2) in human astrocytoma

[Study of COX-2 Expression and Angiogenesis in Non-Small Cell Lung Cancer].

Expression of RANKL and OPG mRNA in apical periodontitis

Expression of Cyclooxygenase‐2 Protein in Colon Disease

Cyclooxygenase-2 in human pathological disease

EXPRESSION AND POSSIBLE ROLE OF CYCLOOXYGENASE-2 IN ORAL SQUAMOUS CELL CARCINOMA

COX-2, MMP-7 Expression in Oral Lichen Planus and Oral Squamous Cell Carcinoma

Correlation between pro-inflammatory cytokine expression and clinical data in apical granuloma

Expression and Cellular Localization of Cox-1 And-2 in Helicobacter Pylori Gastritis

[Expression and Function of Cyclooxygenase-2 in Endometrial Carcinoma].

Expression of Cyclooxygenase -2 in Skin Carcinoma and Its Clinical Significance

Cyclooxygenase-2 Expression in Thyroid Nodules.

Cyclooxygenase-2 Expression Is Up-Regulated In Human Pancreatic Cancer

The Relationship Between the Expression of PGE2 and COX-2 and the Osteogenic Activity and Oxygen Level of Alveolar Bone

Study on the Mechanism of RANKL in Bone Absorption of Periapical Lesion

Expression of Cyclooxygenase-2 in Colorectal Cancer and Its Clinical Significance